DRUGS AND MONEY Prices, Affordability and Cost Containment

Mohamed Salama

Egyptian Journal of Rheumatology & Clinical Immunology · 2014 · 38 citations · 1 references

DOIFull text

Open access

Concepts

Abstract

The U.S. Food and Drug Administration on 6 th of Dec approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Approval represents a significant shift in the treatment paradigm for patients with chronic hepatitis C. Sovaldi is a nucleotide analog inhibitor that blocks a specific protein needed by the hepatitis C virus to replicate. Sovaldi is to be used as a component of a combination antiviral treatment regimen for chronic HCV infection. Depending on the genotype of HCV infection a patient has, the treatment regimen could include Sovaldi and ribavirin or Sovaldi, ribavirin and peginterferon-alfa. In clinical studies, Sovaldi in combination with other agents achieved very high cure rates while shortening the duration of treatment to as little as 12 weeks and reducing or completely eliminating the need for interferon injections, depending on the viral genotype. (1) These are the good news but the bad news that daily pill costs 1000 $ = 7000 LE, a 24-week supply of the drug will cost 168000 $ = 1,176,000 LE??? What a price !!! Hepatitis C virus is a major health problem in Egypt with estimates of about 14 millions patients with active infection at time being, the highest world prevalence. This means that we need more than 250 billion $ to treat our patients, what a price!!! Extensive research over the past 2 decades has led to the development of a new and exciting group of biologic therapies. These agents have begun to revolutionize the treatment of rheumatoid arthritis and other forms of immune mediated inflammatory rheumatic diseases . They are clearly very effective medications and may significantly change the course of these diseases. Biologics may induce remission in various inflammatory rheumatic diseases, thereafter allowing maintenance with less expensive medications There are seven biologic agents available now in Egypt, but there is no data base available to know the exact number of patients on biologics and the indications for prescribing a particular biologic as there is no biologic

References

1